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Abstract 
This paper presents a cost-effectiveness analysis (CEA) of paediatric ARV administration in Zambia using 
cotrimoxazole as a comparator. The CEA was facilitated by the paediatric formulations provided by the Indian 
company Cipla Limited for the CHAPAS (Children with HIV in Africa – Pharmacokinetics and Adherence of 
Simple Antiretroviral Regimens) randomized controlled trials. The study design for ARVs was an open, 
randomised and controlled phase I and II trial, in which 220 children were recruited using a set of inclusive and 
exclusive criteria and randomised on the basis of 1:1 ratio. Two models were used for analysis: Cost-effectiveness 
analysis and the Markov stochastic model. The integrated results on a number of outcomes such as the CD4 
distribution over time, cost estimates, estimates of transition probabilities, estimates of life expectancy, survival 
curves, incremental cost effectiveness ratios and net health benefits attest the dominance of the ARVs over 
cotrimoxazole and its high desirability of use as a vital complement to the comparator drug which has its own 
merit as a low-cost intervention.. 
Keywords: Paediatric ARV, Incremental Cost Effectiveness Ratio, Markov model, net health benefits, survival 
analysis 
 
1 Introduction 
Life-prolonging antiretroviral (ARV) medication became available soon after the advent of HIV/AIDS. However, 
the access to these ARVs was severely limited in low-resource settings, especially for children for whom 
formulations did not exist until the latter half of 2000. To bridge this gap, paediatric formulations were developed.  
This paper presents a cost-effectiveness analysis (CEA) of paediatric ARV administration in Zambia using 
cotrimoxazole as a comparator. The paediatric ARV was Pedimune, a fixed-dose composition of three drugs - 
Stavudine, Lamivudine and Nevirapine.  
The use of CEA for decision making to support choices in the selection of interventions has been weak in 
Zambia. Such an analysis could therefore provide norms for public choice decisions that improve social welfare 
in a country like Zambia that is chronically constrained by resources. 
The CEA was facilitated by the paediatric formulations provided by the Indian company Cipla Limited for 
the CHAPAS (Children with HIV in Africa – Pharmacokinetics and Adherence of Simple Antiretroviral Regimens) 
randomized controlled trials. Such trials provide acceptable international practice standards in patient level data 
collection and analysis for CEA (Drummond et al, 2008). 
 
2 Study design 
The study design for ARVs was an open, randomised and controlled phase I and II trial, in which 220 children 
were recruited from the health facilities based in Lusaka and randomised on the basis of 1:1 ratio.  Eligible children 
were aged 3 months to 14 years inclusive. Treatment of the children in the two treatment arms was based on 
immediate commencement of ARVs with Pedimune for the first one at full dose. For the other arm the treatment 
was to be dose escalated over a period of two weeks. In the initial two weeks this therefore entailed a treatment 
strategy of 50 per cent NVP including additional 3TC/d4T (Lamivir – S) in tabular form.  In addition, the children 
were randomised on the basis of age within the following age categories: 3 months – 6 years and 7 years and above. 
The children were recruited on the basis of certain inclusion and exclusion criteria as shown below: 
 
2.1 Inclusion criteria  
Participation in the study included children with the following characteristics: Children aged between 6 months to 
14 years inclusive; children with an HIV-positive status, as determined by positive antibody test in children greater 
than 18 months or positive proviral DNA in children  less than18 months; those  previously untreated with 
antiretrovirals, including any ART given to prevent mother to child transmission, and if they further fulfilled the 
following conditions: 
• They met one of the WHO criteria for initiating treatment which included either of:  
• CD4 < 15% if > 18 months of age, or < 20% if < 18 months of age;  
• WHO paediatric stage 4 or severe stage 3 disease  regardless of CD4 %; 
• WHO paediatric stage 2 disease with consideration of CD4 % (<15 for children > 18 months, <20 
for children < 18 months).  
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2.2 Exclusion criteria  
The following were excluded: 
i. Children who were unwilling or could not regularly attend the CHAPAS trial centre; 
ii. Children who faced severe laboratory abnormalities (contraindicated NVP based regimen), i.e. serum 
creatinine > 5 times upper limit of normal (ULN) or levels of enzymes AST or ALT > 10 times ULN; 
iii. Children who had active opportunistic infection and/or serious bacterial infection at the time of study 
entry  including TB (children may be enrolled after the acute phase) and whose life expectancy was less 
than four weeks; 
iv. Children who had current treatment with any medication known to be contra-indicated with any of the 
drugs prescribed for the patient’s ART therapy in this trial, including Rifampicin.  
The CHAPAS trial: The CHAPAS trial, as previously mentioned was developed to determine among other 
issues the efficacy of newly formulated three in one paediatric ARVs. It involved the following procedures: 
 
2.3 ARV administration  
ARV administration was monitored on a continuous basis through clinic visits and home visits by both the 
guardians and clinicians. In addition the following tests were conducted: 
• Laboratory tests that included: Haematology (haemoglobin, MCV, platelets, white cell count, 
neutrophil and lymphocyte counts); 
•  Biochemistry (Creatine, ALT, AST, bilirubin); Lymphocyte subsets (CD3 – absolute and  
percentage), CD3 + CD4 (absolute and percentage); CD3 + CD8 (absolute and percentage); Total 
lymphocyte count; 
• Cells and plasma: Virology ( HIV – 1 RNA using an ultrasensitive assay) 
 
2.4 Data recording  
Data was recorded on case report forms (CRFs). The data collected was recorded in the trial data management 
system while copies were backed up in the clinical trial clinic. 
 
3 Analytical models 
Two models were used for analysis – the Cost Effectiveness Analysis (CEA) model to calculate Incremental Cost 
Effectiveness Ratios (ICERs) and a Markov model to calculate stochastic net benefits. 
 
3.1 Cost Effectiveness Analysis model  
The ICERs were calculated using the following formula: 
ICER =  
21
21
EE
CC
−
−
   
Where 
C1 = costs related to Treatment Strategy or Intervention X1 (Cotrimoxozole in our case) 
C2 = costs related to alternative Treatment Strategy or Intervention X2 (Paediatric ARV) 
E1 = the clinical outcomes or effects ascribed to Treatment Strategy X1 
E2 = the clinical outcomes or effects ascribed to Treatment Strategy X2 
 
3.2 Net health benefits  
The ICER estimates are subject to uncertainty as explained by Stinnet and Mullahy (1998). In order to limit the 
impacts of problems related to uncertainty and other problems, the concept of Net Health Benefits was developed.  
The decision making framework is stated as follows: 
Assuming, 
i. New treatment therapy (or treatment group) and current treatment standard (or control group) 
ii. Mean treatment cost of new therapy = µCT versus that of the control or current therapy = µCC  
iii. Mean effects of new therapy = µET versus the control or current therapy = µEC, then four scenarios 
arise: 
• µCT - µCC < 0; µET - µEC > 0;  dominance  -  accept the new therapy as it is  cheaper and more effective 
than the current or comparable therapy 
• µCT - µCC > 0; µET - µEC < 0; dominance  -  reject the new therapy as it is more expensive  less effective 
than the current or comparable therapy 
• µCT - µCC > 0; µET - µEC > 0; trade – off  - consider magnitude of additional cost of the new therapy 
relation to additional the additional cost of the existing therapy. 
• µCT - µCC < 0; µET - µEC < 0; trade – off  - consider magnitude of cost-saving  of the new therapy 
relative to its reduced effectiveness 
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As a summary the following decision making rule or equation holds: 
ICER	 =
				
		
		

		= 		
∆	
∆
		< 	R        
 
3.3 Markov model – key concepts  
3.3.1 Absorbing states: The Markov model has defined states of health in which the disease progresses. Disease 
progression is not necessarily irreversible nor is it definite in the sense that within a particular health state, an 
individual need not necessarily progress to a worse state. Each Markov model will have an absorbing state. This 
is the state from which the individual will not ordinarily experience remission or reversal and is normally called 
the dead state. 
The following diagram shows the different states of disease. 
Figure 1: Markov Model showing disease states 
 
Source: Sculpher et al (2000) 
3.3.2 Transition Probabilities: Progression through a given state is indicated by the arrows. In the representation 
above the transition matrix is given by 4 x 4 dimensions meaning that 16 possible transitions exist.  
While the individual transits through various disease progression states, the probability of moving out of a 
given state is not dependant on previous states the person may have encountered.  
 
3.4 Survival analysis 
Survival analysis (or time to event analysis, transition or duration analysis) seeks to determine the time between 
transition and time in state. The outcome of interest in the clinical trials was death. Survival analysis was 
undertaken to determine the clinical outcome. The end of death was used to determine a number of things which 
included among others, the resource use up to the time of death, the number of persons living, survival rates, 
transition probabilities and life expectancy. 
The survival analysis using the Kaplan – Meier analysis proceeds by assuming replacement. If survival time 
is defined as t1, the cohort or sample size is n1 and the censoring event affects d1, as a share of the sample, the 
Kaplan – Meier estimator, S(t1) is determined by the following: 
In time or period t1 the number of patients who died over the total sample is equal to the probability of 
surviving = n1 - d1, or alternatively: 
Probability	of	surving	, Pr	 =
	 
	! 
 
  
This process is iterative until censoring ends or the cohort is eliminated. This typically may not happen in a 
clinical trial due to the budget limitation or time to ensure follow up of the natural course of time to natural event 
for all subjects. 
With each censoring event (death) the Kaplan – Meier curve drops, with the (vertical) distance or drop 
reflecting the number of censored events. The probabilities of dying in the two arms under consideration are by 
observation of the curves shown to be much higher for the cotrimoxazole arm in comparison to the ARV arm 
where the vertical drops are smoother than the former.  
 
3.5 Costing  
Costing was done of the following items: 
• Costing of the main items such as medications was based on resource use or consumption and valued at 
market prices using the WHO Drug Price List.  
• Human resource costs were estimated using proportion of time spent by patients and the number of 
Asymtomatic 
disease state
Progressive 
disease state 
Progression 
disease state 
Dead state 
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contact time per patient valued by the share of total wage and salary costs by the different skills.   
• The building costs are estimated as the share of space occupied and number of paediatric cases with 
HIV/AIDS as a share of the total paediatric attendance.  
• Costs of opportunistic infections were calculated on the basis of hospitalisation costs and costs of 
opportunistic infection medications.  
 
3.6 Markov chain modelling  
Living with HIV/AIDS in all likelihood provides a risk of a long term process that relates to HIV/AIDS being 
considered a chronic condition. The cohort under consideration in this case had already been infected. 
Consequently, the typical representation of Markov chain process may be depicted in three generic states of well, 
ill and death. In this case, the identified states comprise HIV infection in asymptomatic state as well as the two 
depicting ill health and death. Although some of the subjects in the study may well have initially transitioned from 
well state to ill, most subjects were already infected by way of mother to child transmission.  
In the Markov model depicted in Figure 2 showing the patient cycle, the transition probabilities are estimated 
based on the Kaplan – Meier method. The circles show a specific health condition or health state. In this case, the 
health states can be defined in terms of the differences in the CD4 count and/or percentage. Given the complexities 
of appropriately distinguishing the status of children under 5 in terms of their CD4 counts, a preference for CD4 
percentage i.e. CD4 lymphocyte cells as a percentage of total lymphocytes has been advocated (WHO, 2006, Dunn 
et al, 2008). The arrows demonstrate the progression related with transition between or among the different states 
or disease conditions. In addition, all the different disease conditions obtain under the two different treatment arms 
of the cohort.  The patient life cycle is estimated using Monte Carlo simulation.  
Figure 2: State – Transition Markov model 
 
4 Results and their interpretation 
We now present the various results emerging from our analysis and their interpretation. 
 
4.1 CD4 percentage distribution over time  
The following histograms show the distributions of the CD4 percentage of the cohorts from initiation of the clinical 
trials to the end. The data shows the skewness of the CD4 cells over time and the concentration in CD4 as 
medication was available consistently for the cotrimoxazole and ARV cohorts. Over the duration of the trial, given 
all the quarterly readings for CD4 percentage and other data, the cohort distribution for cotrimoxazole shows a 
leftward skewed beta distribution. The ARV cohort on the other hand is right skewed.  
  
Markov Process for Paediatric ART 
Regressive state transition cycle
Progresive state transition cycle
Asymptomatic 
State:CD% >25 <35 
Advanced: CD% 15 -
29 
Severe 15-25% CD4  
or <200 cells/mm3
Mild: CD4 % 20 - 35
Dead State = 0
HIV Associated Clinical Disease
Asymptomatic 1
Mild 2
Advanced 3
Severe 4
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Figure 3: CD4 Percentage Distribution of the Cotrimoxazole Cohort 
 
Source:  Authors’ construction 
 
Figure 4: CD4 Percentage Distribution of the ARV Cohort 
 
Source: Authors’ construction 
 
4.2 Cost structures 
Table 1: Cost Estimates for Cotrimoxazole Cohort 
Variable    Mean  Standard deviation Minimum Maximum 
Total inpatient cost (hospitalization costs)    250  446.45 0 3859 
Total medical costs     45.6  132.8 0 2092 
Physician and nursing costs    21.7  7.9 1 115 
Laboratory costs     15  0 15 15 
Total costs per person   752  551.8 1 4252 
Source: Authors’ computations 
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Table 2: Cost Estimates for Antiretroviral Cohort 
Variable Mean costs 
(US$) 
Standard 
deviation 
Minimum Maximum 
Physician costs 65.7 21.8 6 107 
Nursing costs 14.7 4.4 1 23 
ART costs (including other drugs for outpatient 
prescriptions) 
90.4 70.9 0 307 
Total inpatient cost (hospitalisation) costs inclding 
drugs) 
13.4 32.6 0 516 
Laboratory costs 15.0 0.0 15 15 
Total costs per person 201.5 95.2 24 791 
Source: Authors’ computations 
The structure of the costs for the two treatment arms shows quite diverse results. The costs for ARV are on 
the whole comparatively low. In particular, the hospitalisation costs are markedly lower than the corresponding 
costs for cotrimoxazole. The higher hospitalisation costs in the case of cotrimoxizole also reflect the frequency of 
hospitalisations and the higher costs related to the incidence of opportunistic infections. The cost structures 
ultimately have a key bearing on the final effectiveness results. 
 
4.3 Transition probability estimates 
The transition probabilities were obtained using the approach by Chancellor et al (1997). The progression of the 
disease over time is shown in a four dimensional Markov model. This captures the staging phases of HIV in terms 
of the states relating to asymptomatic, symptomatic (severe and AIDS) and death. 
Table 3 below provides the transition probabilities. 
Table 3: Transition probabilities 
TRANSITION 
PROBABILITIES  
   
Parameter 
 
Value  Value   
Treatment Arm  Summary of Transition 
Formulation 
1.Cotrimoxazole 2.Antiretroviral 
therapy 
Transition probability to A to A TP_A_A 0.72 0.9 
Transition probability to A to B TP_A_B 0.18 0.08 
Transition probability to A to C TP_A_C 0.098 0.0019 
Transition probability to A to D TP_A_D 0.002 0.001 
        
Transition probability to B to A TP_B_A 0   
Transition probability to B to B TP_B_B 0.64 0.748 
Transition probability to B to C TP_B_C 0.34 0.238 
Transition probability to B to D TP_B_D 0.02 0.014 
        
Transition probability to C to A TP_C_A 0   
Transition probability to C to B TP_C_B 0   
Transition probability to C to C TP_C_C 0.6 0.72 
Transition probability to C to D TP_C_D 0.4 0.28 
Transition probability to D to D TP_D_D 1 1 
Source: Authors’computations 
Note: The transition of an individual, say Individual Y from one state of being to another, reflects in the modelling 
process the risk of Individual Y changing her/his status based on changes to the CD4 count and therefore her/his 
ability to survive within the current state, on  the basis of the assumptions of the Markovian states. TP = Transition 
Probability 
In general the comparative probabilities for the cotrimoxazole group are lower than for the ARV group. 
 
4.4 Estimates of life expectancy and survival curves 
Life expectancy was estimated based on the approach of the declining exponential approximation of life 
expectancy (DEALE). This assumes that survival rate is dependent on a simple exponential function (Beck JR et 
al, 1983).  
Table 4 below shows the estimates of life expectancy for the cotrimoxozole and ARV cohorts. 
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Table 4: Life expectancy estimates 
Years in state A B C Life expectancy (Additional years) 
Cotrimoxazole 3.6 1.8 2.4 7.7 
ARVs 4.8 1.9 2.3 8.9 
Source: Authors’ computations 
The better performance on life expectancy of the ARVs is clearly brought out in the above table. 
The expected life expectancy survival curves are shown in Figure 4 below. The derived survival curves are 
based on an assumed sample of 1000 iterations (obtained through bootstrapping) and a 20-year period.  
Figure 4: Expected life expectancy (in years) survival curves 
 
Source: Authors’ construction 
Again, the survival rates shown by the curves in the figure above demonstrate the clear capacity of the ARVs 
to extend life expectancy and shift the curves outwards as a result of increased life expectancy.  
 
4.5 Computed incremental cost effectiveness ratios (ICERs) 
Table 5 shows the ICERs for the two treatments. 
Table 5: Computed Incremental Cost Effectiveness Ratios 
  Cotrimoxazole ARVs 
Expected cost $3,735 $3,356 
Life-years 6.51 7.53 
Incremental cost 
 
-379.06 
Incremental outcome 
 
1.0166 
ICER   -$373 
Source: Authors’ construction 
Theoretically negative ICERs are considered problematic to interpret according to Briggs and Gray (1999) 
and Stinnett and Mullahy (1998). However, as shown by Stinnett and Mullahy as well as Briggs and Gray, if the 
ICER is identified to be in quadrant II of the cost–effectiveness plane, then the new therapy or technology is clearly 
dominant and the complications do not arise. The interpretation is more definitive as the change in the ICER 
denotes the cost alleviated or saved as a result of the new technology.  
 
4.6 Net benefit estimates 
The net benefits as shown in Table 6 below are positive in all cases fulfilling the conditionality and confirming the 
greater gains accruing by administration of ARVs in relation to cotrimoxazole. When the range of threshold values 
(lambda) is changed, it is observed that the net benefits are even greater for higher thresholds. 
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Table 6: Net benefit estimates 
Descriptive statistics for Net Benefit Net Benefit (US$) 
Given Λ = US$1,500 
Net Benefit (US$) 
Given Λ = US$5,000 
Mean 21,310 69,729 
Median 21,309 69,729 
2.5th percentile  21,131 69,277 
97.5th percentile 21,506 70,147 
Minimum 20,990 69,010 
Maximum 21,633 70,463 
 Source: Authors’ construction 
 
5 Conclusion 
The results of our analysis show that the ICERs favour paediatric ARVs in comparison to the cotrimoxazole. The 
policy recommendation that emerges from this is that paediatric ARVs constitute a necessary intervention in the 
care and management of children living with HIV/AIDS in the same way as adults have access to adult 
formulations.  
These results in fact corroborate the results of another recent study by Chitah, Jonsson and Seshamani (2016) 
on the Health Related Quality of Life (HRQoL) that shows that the administration of paediatric ARVs brings about 
a very big improvement in the HRQoL of children. 
Further, though the results are in favour of ARVs, the results of cotrimoxazole as earlier reported by Mairin 
R et al (2008) show that cotrimoxazole is itself cost effective given the option of doing nothing as was the case at 
the time or using it to lower infections of opportunistic illnesses as well as delayed advent of AIDS and immunity 
decline.  
All these combined results demonstrate the economic and social gain of adopting and providing public health 
management of HIV/AIDS using both cotrimoxazole as a low cost intervention and ARVs to sustain the life 
expectancy of the individual beyond what hopelessness previously existed.  
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